Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.

CONCLUSIONS: Osilodrostat was efficacious in decreasing cortisol levels and safe in treating patients who have failed or are ineligible for pituitary surgery. Although risks exist, a pivotal clinical trial revealed efficacy in 86% of participants.
PMID: 33143437 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - November 3, 2020 Category: Drugs & Pharmacology Authors: Dougherty JA, Desai DS, Herrera JB Tags: Ann Pharmacother Source Type: research